+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Muscular Dystrophy - Pipeline Review, H2 2019

  • ID: 4894178
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 233 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AAVogen Inc
  • Benitec Biopharma Ltd
  • Dyne Therapeutics Inc
  • GlaxoSmithKline Plc
  • Nexien Biopharma Inc
  • ReveraGen BioPharma Inc
  • MORE
Muscular Dystrophy - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H2 2019, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 6, 39, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 6 molecules, respectively.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AAVogen Inc
  • Benitec Biopharma Ltd
  • Dyne Therapeutics Inc
  • GlaxoSmithKline Plc
  • Nexien Biopharma Inc
  • ReveraGen BioPharma Inc
  • MORE
Introduction
Muscular Dystrophy - Overview
Muscular Dystrophy - Therapeutics Development
Muscular Dystrophy - Therapeutics Assessment
Muscular Dystrophy - Companies Involved in Therapeutics Development
Muscular Dystrophy - Drug Profiles
Muscular Dystrophy - Dormant Projects
Muscular Dystrophy - Discontinued Products
Muscular Dystrophy - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Muscular Dystrophy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Muscular Dystrophy - Pipeline by AAVogen Inc, H2 2019
Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H2 2019
Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H2 2019
Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical Inc, H2 2019
Muscular Dystrophy - Pipeline by Audentes Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Avidity Biosciences LLC, H2 2019
Muscular Dystrophy - Pipeline by Benitec Biopharma Ltd, H2 2019
Muscular Dystrophy - Pipeline by Biophytis SA, H2 2019
Muscular Dystrophy - Pipeline by CalyGene Biotechnology Inc, H2 2019
Muscular Dystrophy - Pipeline by Casma Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2019
Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, H2 2019
Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by CRISPR Therapeutics AG, H2 2019
Muscular Dystrophy - Pipeline by Dyne Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Elixirgen Therapeutics LLC, H2 2019
Muscular Dystrophy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2019
Muscular Dystrophy - Pipeline by Expansion Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Facio Therapies BV, H2 2019
Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Genea Biocells, H2 2019
Muscular Dystrophy - Pipeline by Genzyme Corp, H2 2019
Muscular Dystrophy - Pipeline by Gilead Sciences Inc, H2 2019
Muscular Dystrophy - Pipeline by GlaxoSmithKline Plc, H2 2019
Muscular Dystrophy - Pipeline by Keros Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Locana Inc, H2 2019
Muscular Dystrophy - Pipeline by ML Bio Solutions Inc, H2 2019
Muscular Dystrophy - Pipeline by Myogem Health Company SL, H2 2019
Muscular Dystrophy - Pipeline by NeuBase Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Nexien Biopharma Inc, H2 2019
Muscular Dystrophy - Pipeline by Nymirum Inc, H2 2019
Muscular Dystrophy - Pipeline by Pfizer Inc, H2 2019
Muscular Dystrophy - Pipeline by Phrixus Pharmaceuticals Inc, H2 2019
Muscular Dystrophy - Pipeline by Prothelia Inc, H2 2019
Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
Muscular Dystrophy - Pipeline by Resverlogix Corp, H2 2019
Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H2 2019
Muscular Dystrophy - Pipeline by SanBio Inc, H2 2019
Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2019
Muscular Dystrophy - Pipeline by Sarcomed AB, H2 2019
Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H2 2019
Muscular Dystrophy - Pipeline by Seelos Therapeutics, Inc., H2 2019
Muscular Dystrophy - Pipeline by Siwa Therapeutics, H2 2019
Muscular Dystrophy - Pipeline by Tamid Bio Inc, H2 2019
Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2019
Muscular Dystrophy - Pipeline by Xonovo Inc, H2 2019
Muscular Dystrophy - Dormant Projects, H2 2019
Muscular Dystrophy - Dormant Projects, H2 2019 (Contd..1), H2 2019
Muscular Dystrophy - Dormant Projects, H2 2019 (Contd..2), H2 2019
Muscular Dystrophy - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Muscular Dystrophy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AAVogen Inc
  • Achelios Therapeutics Inc
  • AMO Pharma Ltd
  • Armgo Pharma Inc
  • Asklepios BioPharmaceutical Inc
  • Audentes Therapeutics Inc
  • Avidity Biosciences LLC
  • Benitec Biopharma Ltd
  • Biophytis SA
  • CalyGene Biotechnology Inc
  • Casma Therapeutics Inc
  • Catabasis Pharmaceuticals Inc
  • Constant Therapeutics LLC
  • Corcept Therapeutics Inc
  • CRISPR Therapeutics AG
  • Dyne Therapeutics Inc
  • Elixirgen Therapeutics LLC
  • Exodos Life Sciences Limited Partnership
  • Expansion Therapeutics Inc
  • Facio Therapies BV
  • Fulcrum Therapeutics Inc
  • Genea Biocells
  • Genzyme Corp
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Keros Therapeutics Inc
  • Locana Inc
  • ML Bio Solutions Inc
  • Myogem Health Company SL
  • NeuBase Therapeutics Inc
  • Nexien Biopharma Inc
  • Nymirum Inc
  • Pfizer Inc
  • Phrixus Pharmaceuticals Inc
  • Prothelia Inc
  • PTC Therapeutics Inc
  • Recursion Pharmaceuticals Inc
  • Resverlogix Corp
  • ReveraGen BioPharma Inc
  • SanBio Inc
  • Santhera Pharmaceuticals Holding AG
  • Sarcomed AB
  • Sarepta Therapeutics Inc
  • Seelos Therapeutics, Inc.
  • Siwa Therapeutics
  • Tamid Bio Inc
  • Ultragenyx Pharmaceutical Inc
  • Xonovo Inc
Note: Product cover images may vary from those shown
Adroll
adroll